Skip to main content

Table 1 Distribution of reported clinical traits among CLL patients

From: Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival

Clinical traits

Description

Number of patients with reported information

Age at diagnosis

Age patient was when diagnosed with disease

203

Survival days

Length of time patient survived (days) since primary diagnosis

203

Binet stage B

Patients diagnosed with Binet Stage B CLL

15/203

Binet stage A

Patients diagnosed with Binet Stage A CLL

179/203

Binet stage C

Patients diagnosed with Binet Stage C CLL

8/203

Male

 

116/203

Female

 

78/203

Relapse interval

Length of disease-free interval (days) following primary treatment

92/203

Relapse

Patients with reported relapse event

92/203

Chemotherapy

Patients who received chemotherapy as first treatment

24/203

No treatment

Patients who did not receive any therapy

9/203

IGHV mutated

Patients with Immunoglobulin Heavy Chain mutations

132/203

IGHV unmutated

Patients without Immunoglobulin Heavy Chain mutations

65/203

SF3B1 mutated

Patients with any SNP mutations in the SF3B1 gene

19/203

ATM mutated

Patients with any mutations in the ATM gene

18/203

  1. These clinical traits were correlated with transcriptome module eigengenes that were identified during the Weighted Gene Co-Expression Network Analysis (WGCNA)